ArticleBMC cancer2025
Lipidomic and transcriptomic analysis and its therapeutic implications in Chinese Kazakh patients with esophageal squamous cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Advances in multi-omics for esophageal squamous cell carcinoma: diagnostic, prognostic, and therapeutic perspectives.Protein & cell · 2026Review
- Mast cell driven immunometabolism as a therapeutic entry point in ESCC.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo analyze the lipidomic profile of ESCC patients, link changes in cancer lipid metabolism to gene expression changes, and provide new insights into the diagnosis and treatment of ESCC patients in the Kazakh Xinjiang ethnic group.
methodsBy integrating the lipidome and transcriptome results, genes related to differential lipid metabolites in Kazakh ESCC patients were identified, and the effects of the key gene AMPK on lipid metabolism in ESCC cells were investigated by ultra-performance liquid chromatography/tandem mass spectrometry (UPLC‒MS/MS).
resultThrough absolute lipid quantification analysis of two serum samples, 13 classes of lipids were detected, with triglycerides (TAGs) being the most abundant. Phosphatidylcholine (LPC), phosphatidylethanolamine (PE), and ceramide (Cer) were the lipid categories with significant differences between the two groups. Transcriptome analysis revealed that genes related to fatty acid synthesis, carnitine biosynthesis, and other lipid metabolism pathways were enriched in the tumor tissue. Integrative analysis of the two groups suggested that fatty acid synthesis, fatty acid metabolism, lipid degradation, cholesterol metabolism, and the AMPK signaling pathway were enriched in tumor tissue. UPLC‒MS/MS was used to perform targeted lipidomic analysis of AMPK-knockdown esophageal squamous cell carcinoma cells, suggesting that AMPK may be involved in the reprogramming of lipid metabolism in Kazakh ESCC patients.
conclusionsLipid metabolic reprogramming occurs in the tumor tissue of Kazakh ESCC patients, and there is a correlation between AMPK activity and lipid metabolism, which suggests a potential therapeutic target for the treatment of Kazakh ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.